Serious adverse events occurred in @ ( @ % ) of @ patients receiving desmoteplase compared with @ ( @ % ) of @ patients receiving placebo ; frequency of symptomatic intracranial haemorrhage ( six -LSB- @ % -RSB- patients in the desmoteplase group vs five -LSB- @ % -RSB- in the placebo group ) , symptomatic cerebral oedema ( five -LSB- @ % -RSB- vs four -LSB- @ % -RSB- ) , and major haemorrhage ( ten -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) was much the same between treatment groups .